Treatment of resistance to vepotuzumab (POLIVY)

Vepotolizumab (POLIVY) is a drug that targetsCD79b-positive diffuse large B-cell lymphoma (DLBCL). Sometimes patients may develop resistance to this drug. Vepotuzumab may be given in combination with other drugs, such as chemotherapy drugs, immunotherapy, or other targeted therapies. This strategy can simultaneously attack cancer cells through multiple pathways and improve the therapeutic effect.

Immunotherapy methods for DLBCL include CAR-T cell therapy and PD-1/PD-L1 inhibitors. These treatments can enhance the patient's own immune system's response to the tumor and improve treatment effects. After vepotuzumab fails, drugs with different mechanisms can be tried for treatment. Tumor cells can be genetically sequenced and mutated. Switching to other targeted drugs or immunotherapy with different modes of action may respond to vepotuzumab resistance.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.